✦ LIBER ✦

Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults

✍ Scribed by Wendy A. Keitel; Cornelia L. Dekker; ChrisAnna Mink; James D. Campbell; Kathryn M. Edwards; Shital M. Patel; Dora Y. Ho; Helen K. Talbot; Kuo Guo; Diana L. Noah; Heather Hill

Book ID: 116961479
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 338 KB
Volume: 27
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2009.03.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and immunogenicity of a subvirion

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

✍ Rebecca C. Brady; John J. Treanor; Robert L. Atmar; Wendy A. Keitel; Robert Edel 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 302 KB

Safety and immunogenicity of two differe

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine

✍ Paul A. Tambyah; Annelies Wilder-Smith; Borislava G. Pavlova; P. Noel Barrett; H 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 253 KB

Phase I and II randomised trials of the

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults

✍ Terry M. Nolan; Peter C. Richmond; Maryanne V. Skeljo; Georgina Pearce; Gunter H 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 591 KB

Immunogenicity and Safety of Varying Dos

Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons

✍ Jackson, L. A.; Chen, W. H.; Stapleton, J. T.; Dekker, C. L.; Wald, A.; Brady, R 📂 Article 📅 2012 🏛 University of Chicago Press 🌐 English ⚖ 221 KB

Assessment of the immunogenicity and saf

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects

✍ Hiroyuki Fukase; Hidetoshi Furuie; Yuji Yasuda; Ryoya Komatsu; Kenji Matsushita; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 397 KB